The case for intraocular delivery of PPAR agonists in the treatment of diabetic retinopathy.

Hdl Handle:
http://hdl.handle.net/10147/283772
Title:
The case for intraocular delivery of PPAR agonists in the treatment of diabetic retinopathy.
Authors:
Treacy, Maxwell P; Hurst, Tara P
Affiliation:
Royal Victoria Eye and Ear Hospital, Adelaide Road, Dublin 2, Dublin, Ireland. max@treacy.ie
Citation:
The case for intraocular delivery of PPAR agonists in the treatment of diabetic retinopathy. 2012, 12:46 BMC Ophthalmol
Journal:
BMC ophthalmology
Issue Date:
Sep-2012
URI:
http://hdl.handle.net/10147/283772
DOI:
10.1186/1471-2415-12-46
PubMed ID:
22937835
Additional Links:
http://www.biomedcentral.com/content/pdf/1471-2415-12-46.pdf; http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3532122/pdf/1471-2415-12-46.pdf
Abstract:
Systemic therapeutics targeting the peroxisome proliferator-activated receptors have been found to be beneficial in the treatment of diabetic retinopathy. In this paper, we provide a rationale for the use of these therapeutics as intraocular agents. In addition, we introduce the peroxisome proliferator-activated receptors and describe their functions in response to the drugs.
Item Type:
Article
Language:
en
MeSH:
Diabetic Retinopathy; Eye; Fenofibrate; Humans; Hypolipidemic Agents; Injections; PPAR alpha; Treatment Outcome
ISSN:
1471-2415

Full metadata record

DC FieldValue Language
dc.contributor.authorTreacy, Maxwell Pen_GB
dc.contributor.authorHurst, Tara Pen_GB
dc.date.accessioned2013-04-24T11:45:26Z-
dc.date.available2013-04-24T11:45:26Z-
dc.date.issued2012-09-
dc.identifier.citationThe case for intraocular delivery of PPAR agonists in the treatment of diabetic retinopathy. 2012, 12:46 BMC Ophthalmolen_GB
dc.identifier.issn1471-2415-
dc.identifier.pmid22937835-
dc.identifier.doi10.1186/1471-2415-12-46-
dc.identifier.urihttp://hdl.handle.net/10147/283772-
dc.description.abstractSystemic therapeutics targeting the peroxisome proliferator-activated receptors have been found to be beneficial in the treatment of diabetic retinopathy. In this paper, we provide a rationale for the use of these therapeutics as intraocular agents. In addition, we introduce the peroxisome proliferator-activated receptors and describe their functions in response to the drugs.en_GB
dc.language.isoenen
dc.relation.urlhttp://www.biomedcentral.com/content/pdf/1471-2415-12-46.pdfen_GB
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3532122/pdf/1471-2415-12-46.pdfen_GB
dc.rightsArchived with thanks to BMC ophthalmologyen_GB
dc.subject.meshDiabetic Retinopathy-
dc.subject.meshEye-
dc.subject.meshFenofibrate-
dc.subject.meshHumans-
dc.subject.meshHypolipidemic Agents-
dc.subject.meshInjections-
dc.subject.meshPPAR alpha-
dc.subject.meshTreatment Outcome-
dc.titleThe case for intraocular delivery of PPAR agonists in the treatment of diabetic retinopathy.en_GB
dc.typeArticleen
dc.contributor.departmentRoyal Victoria Eye and Ear Hospital, Adelaide Road, Dublin 2, Dublin, Ireland. max@treacy.ieen_GB
dc.identifier.journalBMC ophthalmologyen_GB
dc.description.provinceLeinsteren

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.